AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06314932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD high in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
Study NCT06314932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MD high in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
Study NCT06314932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD low in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
Study NCT06314932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MD low in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
Study NCT04703283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including exercise, diet, stress management, and sleep management
Study NCT04272372 — intervention group
Intervention type: DRUG
Intervention: Ketoprofen
Description: PO and local therapy
Study NCT04600427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
Study NCT06193161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet delivered prolonged exposure
Description: Therapist-supported internet delivered prolonged exposure for eight weeks.
Study NCT04098016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
Study NCT05376059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
Study NCT05376059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How and Why Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
Study NCT05376059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
Study NCT06381882 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic resection
Description: Any kind of pancreatic resection will be included
Study NCT05320224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient-Oriented Music Intervention (POMI)
Description: The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
Study NCT05320289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AblaCare System
Description: The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
Study NCT05792956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using mobile app
Description: Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
Study NCT04876417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Study NCT04876417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Study NCT04583228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX71
Description: Single-dose, intravenous infusion
Study NCT04583228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion
Study NCT04772352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat treatment
Description: According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
Study NCT04772352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study NCT04772352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study NCT04747054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Study NCT06330298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment social cognition and emotion regulation (T-ScEmo)
Description: T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
Study NCT05359536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Early Childhood educators in PA
Description: The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
Study NCT05708365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Lung Protective Ventilation
Description: ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute
Study NCT05708365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-Lung Protective Ventilation
Description: ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute
Study NCT04235361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Differential RPA tests
Description: The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
Study NCT04814706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate drinking
Description: Administration of carbohydrate fluid
Study NCT04589832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1
Description: Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
Study NCT04589832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
Study NCT06026800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-R01
Description: Personalized mRNA vaccine encoding neoantigen, IH injection
Study NCT04747054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Study NCT04747054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Loco-regional radiotherapy
Description: Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy.
Study NCT05691842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT intervention
Description: Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
Study NCT05691842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task intervention
Description: Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
Study NCT05603182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA052
Description: PRA052
Study NCT05603182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04747054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles
Study NCT04747054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles
Study NCT05719350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for Knee
Description: Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
Study NCT05719350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises for Knee
Description: Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
Study NCT06151613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous eCTG monitoring using the NFMS
Description: Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
Study NCT05027776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses Group among 9-14 years
Description: Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
Study NCT05027776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses Group among 9-19 years
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study NCT05027776 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3-doses Group among 20-26 years
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study NCT05098249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum
Description: The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
Study NCT05098249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
Study NCT04809649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: Participant will receive treatment with SUBA-itraconazole
Study NCT06432491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking cold water
Description: Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
Study NCT04759612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Participants will watch an upper extremity functionality test.
Study NCT05310968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban hydrochloride sodium chloride injection
Description: Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
Study NCT05310968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirofiban hydrochloride sodium chloride injection placebo
Description: Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
Study NCT05310968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
Study NCT05310968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
Study NCT04815512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests.
Description: serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
Study NCT04815512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: creatinine , urea and serum uric acid will be analysed in the serum.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentail 0.1 ug/kg was administered for sedation induction.
Study NCT05750056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentail 0.1 ug/kg was administered for sedation induction.
Study NCT05965050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myofascial Release Technique
Description: myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
Study NCT05965050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms